The stock has been halted and awaits being reopened
The FDA has approved Biogen’s Alzheimer drug Aducanumab using an accelerated approval pathway. The FDA does require Biogen to conduct a postapproval clinical trial and said that they can take away the approval upon unfavorable results.
The stock was halted for trading at $286.3050 and awaits reopening.